Talk:Baricitinib

Can we relate the structure to its pharmacological properties
Which groups make it a jak inhibitor, and what do the other parts of the molecule do ? - Rod57 (talk) 11:48, 27 April 2016 (UTC)

Needs summary of clinical trials, side-effects etc
FDA Says 'No' to Baricitinib for Rheumatoid Arthritis - Dosages and safety were noted as concerns mentions both. EU likely to approve both 2mg and 4mg/day? but FDA didn't like either dose. - Rod57 (talk) 12:13, 18 April 2017 (UTC)

See also New article on The Lancet
Baricitinib for COVID-19: a suitable treatment? – Authors' reply --Lamiot (talk) 11:50, 5 April 2020 (UTC)
 * https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30304-4/fulltext
 * https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30270-X/fulltext

Another possible use
"in vivo administration of baricitinib, an inhibitor of Janus kinases 1 and 2 (JAK1/JAK2) which are downstream of IFNGR and IL6R, also prevents GvHD while preserving GvL in our preclinical murine model." (https://ashpublications.org/blood/article/132/Supplement%201/3311/264792/Baricitinib-Prevents-and-Treats-GvHD-through-Both ) -- John Broughton (♫♫) 18:48, 27 April 2020 (UTC)

The summary should mention this drug is only for hospitalized covid-19 patients, not for outpatients(treatment at home)
Now it takes several minutes to find this important information from this very long article.

The very end of the article finally tells:

"In May 2022, the FDA approved use of baricitinib for the treatment of adult patients hospitalized with COVID-19 who require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation with a recommended dose of 4 mg once daily for 14 days or until hospital discharge, whichever happens first".

Is it a bad idea to use this drug for outpatients?

ee1518 (talk) 09:32, 26 September 2022 (UTC)